eprintid: 10153332 rev_number: 8 eprint_status: archive userid: 699 dir: disk0/10/15/33/32 datestamp: 2022-08-05 10:40:47 lastmod: 2022-08-05 10:40:47 status_changed: 2022-08-05 10:40:47 type: article metadata_visibility: show sword_depositor: 699 creators_name: Jensen, Nele creators_name: Barry, Andrew creators_name: Kelly, Ann H title: More-than-national and less-than-global: The biochemical infrastructure of vaccine manufacturing ispublished: inpress divisions: C03 divisions: F26 divisions: B03 divisions: UCL keywords: Vaccine R&D, COVID-19, biochemical engineering, infrastructure, equity note: This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third-party material in this article are included in the Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ abstract: The recent efforts to mount an R&D response to public health emergencies of international concern have led to the formation of what we term a biochemical infrastructure of vaccine development and production. In principle, this infrastructure is expected not only to curtail existing pandemics but also anticipate and contain yet-to-emerge future threats. Critically, by nature of its geographical distribution and technical modularity, that infrastructure promises both to accelerate and expand access to essential medical tools, and in so doing, redress global health inequities. In practice, however, the biochemical infrastructure of vaccines remains highly uneven, fragmented and unjust. Moving beyond calls for ‘global health solidarity’, this paper examines the key actors, normative techniques and socio-technical assemblages, from viral platform technologies to intellectual property waivers and from accelerated regulatory pathways to advance market commitments, that serve to link ‘just-in-case’ and ‘just-in-time’ modalities of global health R&D. We argue that the biomedical infrastructure of vaccine development and production emerging in the wake of the COVID-19 pandemic is unfolding across an innovation ecosystem that is more-than-national and yet less-than global: a reconfiguration that may offer possibilities for a new, radically-overhauled, model of vaccine equity. date: 2022-08-01 date_type: published publisher: Informa UK Limited official_url: https://doi.org/10.1080/03085147.2022.2087899 oa_status: green full_text_type: pub language: eng primo: open primo_central: open_green verified: verified_manual elements_id: 1968546 doi: 10.1080/03085147.2022.2087899 lyricists_name: Barry, Andrew lyricists_id: AMBAR34 actors_name: Flynn, Bernadette actors_id: BFFLY94 actors_role: owner full_text_status: public publication: Economy and Society citation: Jensen, Nele; Barry, Andrew; Kelly, Ann H; (2022) More-than-national and less-than-global: The biochemical infrastructure of vaccine manufacturing. Economy and Society 10.1080/03085147.2022.2087899 <https://doi.org/10.1080/03085147.2022.2087899>. (In press). Green open access document_url: https://discovery.ucl.ac.uk/id/eprint/10153332/1/More%20than%20national%20and%20less%20than%20global%20The%20biochemical%20infrastructure%20of%20vaccine%20manufacturing.pdf